Lymphocyte Activation Gene – 3 Protein Market Key Player
Key players operating in the global lymphocyte activation gene – 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.
Ask For Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2027
Immune checkpoint receptors such as lymphocyte activation gene – 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene – 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene – 3 turns off the immune response when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. Moreover, lymphocyte activation gene – 3 protein is associated with T cell exhaustion in which the T cells become desensitized and lose their ability to function.
LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. In cancers, lymphocyte activation gene – 3 expressing exhausted cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at tumor locations. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period.
Lymphocyte Activation Gene – 3 Protein Market Drivers
Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global lymphocyte activation gene – 3 protein market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase II clinical trial and its estimated study completion date is March 16, 2022.
Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date – August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) that are in Phase 1 clinical trials, is expected to be a major factor contributing in global LAG-3 protein market growth over the forecast period.
Manufacturers and researchers are focused on development of novel therapies that aid in treatment of cancer. High prevalence of cancer is expected to boost growth of the market. According to National Cancer Institute, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S., in 2018. The most common types of cancer are lung cancer, breast cancer, prostate cancer, melanoma, bladder cancer, and others. According to Cancer Research UK, 2015, around 54,900 new cases of breast cancer are registered in the UK, which account for 15% of all new cancer cases, annually. Click To Read More On Lymphocyte Activation Gene – 3 Protein Market
Lymphocyte Activation Gene – 3 Protein Market Regional Insights
North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.
High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene – 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.